

ORIGINAL ARTICLE

Antihypertensive, antidyslipidemic and endothelial modulating activities of *Orchis mascula*

Nauman Aziz^{1,2}, Malik Hassan Mehmood^{1,2}, Hasan Salman Siddiqi^{1,2}, Saf-ur-Rehman Mandukhail^{1,3}, Fatima Sadiq¹, Wajiha Maan¹ and Anwarul Hassan Gilani¹

The objective of this study was to investigate the possible mode(s) of action for the medicinal use of *Orchis mascula* (OM) (family *Orchidaceae*) in hypertension and dyslipidemia. In spontaneously hypertensive rats (SHRs), OM significantly ($P < 0.05$) reduced systolic blood pressure to 174.2 ± 9.63 vs. 203.4 ± 7.13 mm Hg (mean \pm s.e.m.; $n = 7-10$) and improved endothelial dysfunction by increasing acetylcholine-induced relaxation. In normotensive anesthetized rats, the crude extract of OM (Om.Cr) at 10 and 30 mg kg⁻¹ caused a dose-dependent attenuation of mean arterial pressure. OM also decreased serum triglycerides to 29.28 ± 6.99 vs. 93.84 ± 5.7 mg per 100 ml ($P < 0.001$), low-density lipoprotein-cholesterol to 5.99 ± 1.27 vs. 21.9 ± 3.5 mg per 100 ml ($P < 0.05$) and atherogenic index to 0.096 ± 0.017 vs. 0.36 ± 0.08 mg per 100 ml ($P < 0.05$). OM significantly reduced lipid levels in tyloxapol and high fat diet-induced hyperlipidemia. In a second model, OM also reduced gain in body weight with a reduction in daily diet consumption. In isolated rabbit aorta, Om.Cr caused concentration-dependent relaxation of both phenylephrine and high K⁺ (80 mM)-induced contractions and a rightward shift of the calcium concentration–response curves similar to the effect seen with verapamil. In conclusion, OM shows antihypertensive and endothelial-modulating effects mediated through multiple pathways that include direct vasodilation by calcium channel blockade and reduction of plasma lipids by inhibition of biosynthesis, absorption and secretion. This study rationalizes the medicinal use of OM in hypertension and dyslipidemia. However, further studies are required to identify the active constituents of this plant.

Hypertension Research (2009) 32, 997–1003; doi:10.1038/hr.2009.148; published online 11 September 2009

Keywords: antidyslipidemic; antihypertensive; calcium antagonist; endothelial dysfunction; *Orchis mascula*

INTRODUCTION

Orchis mascula (OM) Linn. (*syn. Orchis latifolia* Linn., *Dactylorhiza gagariana* Soo), locally known as Saalab misri, belongs to the family *Orchidaceae*. It is found in most parts of Europe and North Africa, as well as in Western and Northern Asia. Iran and Afghanistan are the major commercial sources of the plant. Its roots are used for medicinal purposes. In folk medicine of Pakistan and India, it is prescribed individually or along with other herbs for nervous and muscular, as well as sexual dysfunction and cardiovascular diseases (CVDs). It is also effective in alleviating diarrhea, dysentery and chronic inflammation.¹

The most important constituent of OM is mucilage, comprising 48% of the plant by mass. OM also contains 1% sugar, 2.7% starch, 5% nitrogenous substance and, when fresh, a trace of volatile oil. It yields 2% ash, consisting chiefly of phosphates and chlorides of potassium and calcium. Recently, we reported the antihypertensive, antioxidant, antidyslipidemic and endothelial-modulating activities of a polyherbal formulation (POL-10) that contained OM as one of the ingredients.² However, there are no reports in the literature regarding the biological activity of this plant alone. Therefore, the aim of this

study was to investigate the cardiovascular effects of OM in different animal models to rationalize its medicinal use in hypertension and dyslipidemia.

METHODS

Plant material and extraction

Orchis mascula roots were purchased from a local herbal store in Karachi, Pakistan, and were authenticated by Mr M. Afzal Rizvi, a botanist at the Hamdard University (Karachi). The sample was deposited in the herbarium of the Natural Products Research Division in the Department of Biological and Biomedical Sciences (Aga Khan University, Karachi, Pakistan) with voucher number OM-RT-03-06-70. The roots were ground into fine powder. For the chronic study, OM powder was mixed with diet *ad libitum*. However, for phytochemical and *in vitro* studies, OM powder was soaked in 70% aqueous methanol for 3 days with occasional shaking. It was filtered through a muslin cloth and then through a Whatman qualitative grade 1 filter paper.³ This procedure was repeated three times and the combined filtrate was evaporated using a rotary evaporator at 35–40 °C under reduced pressure of –760 mm Hg to obtain a thick, dark brown, crude extract of OM (Om.Cr), with a yield of ~15.9% (w/w).

¹Natural Product Research Division, Department of Biological and Biomedical Sciences, The Aga Khan University Medical College, Karachi, Pakistan; ²Department of Pharmacology, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan and ³Department of Pharmacy, University of Balochistan, Quetta, Pakistan
Correspondence: Dr AH Gilani, Department of Biological and Biomedical Sciences, The Aga Khan University Medical College, Karachi-74800, Pakistan.
E-mail: anwar.gilani@aku.edu

Received 7 April 2009; revised 27 July 2009; accepted 30 July 2009; published online 11 September 2009

Drugs and standards

Acetylcholine chloride, cholesterol, cholic acid, phenylephrine (PE), phentolamine hydrochloride, norepinephrine, verapamil hydrochloride, potassium chloride and tyloxapol reagent grade were purchased from Sigma Aldrich Chemical Company (St Louis, MO, USA), whereas calcium chloride, glucose, magnesium chloride, magnesium sulfate, potassium dihydrogen phosphate, sodium bicarbonate, sodium chloride and sodium dihydrogen phosphate and methanol used for extraction were purchased from E. Merck KGaA (Darmstadt, Germany). Randox diagnostic kits for serum analyses were purchased from Randox Laboratories (Antrim, UK). Butter fat was purchased from United Bakers (Karachi, Pakistan). All chemicals used were of the highest purity grade. Physiological salt solutions were prepared fresh in distilled water on the day of each experiment, whereas stock solutions of all the drugs and extract were prepared in distilled water or saline and the dilutions were prepared fresh on the day of each experiment.

Animals

Spontaneously hypertensive rats (strain: SHR/NCrBR; hypertensive, non-stroke) and their normotensive controls, Wistar Koyoto (WKY) rats, were imported from the Animal Resource Centre (Australia), at the age of 4 weeks and experiments were started at 20–24 weeks of age. Other animals, such as Sprague–Dawley (SD) rats (170–200 g) and rabbits (1.5–2 kg) of either sex, were sourced locally and housed at the animal house of Aga Khan University. Animals were kept in plastic cages (47×34×18 cm³) with sawdust (changed every 48 h) and were maintained at 23–25 °C with free access to food and water. Rabbits (1–1.2 kg) were starved for 24 h before the experiment and killed by cervical dislocation. All experiments complied with the rulings of the Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council⁴ and were approved by the Ethics Committee of the Aga Khan University (Karachi, Pakistan).

Phytochemical screening

The crude extract was screened for the presence of saponins, flavonoids, tannins, phenols, coumarins, sterols, terpenes, alkaloids and anthraquinones using methods described previously by Tona *et al.*⁵

Preparation of diets

The following four types of diet were prepared:

- Normal diet:** The normal diet was prepared as described previously by Harkness and Wagner⁶ at the animal house of the Aga Khan University, Karachi. The standard diet consisted of flour (5 kg), chokar (5 kg), molasses (150 g), salt (75 g), nutritive-L (33 g), potassium metabisulfite (15 g), oil (500 g), fishmeal (2.25 kg) and powdered milk (2 kg), comprising a total mass of ~13 kg of food material.
- Normal diet with OM:** OM powder was mixed with the normal diet in 3% w/w.
- Atherogenic diet:** Cholesterol (2% w/w), cholic acid (0.5% w/w) and butter fat (5% w/w) were added to the normal diet, as described by Ichihashi *et al.*⁷ with slight modifications.
- Atherogenic diet with OM:** OM (3% w/w) was mixed in diet C.

All measures were taken to ensure the uniform mixing of additives and OM powder in dry ingredients of the diet before kneading.

Pharmacological parameters

Assessment of antihypertensive activity. For the assessment of antihypertensive activity, SHRs were used in the protocol reported by Rodrigo *et al.*⁸ with slight modifications. Male SHRs aged 20–24 weeks were randomly divided into 2 groups ($n=7$ each). For 8 weeks, group 1 was fed diet A (normal diet) and group 2 was fed diet B (normal diet plus OM). WKY rats served as normotensive controls and were fed diet A for the same period. Systolic blood pressure (BP) levels of SHRs were estimated daily using a tail-cuff plethysmograph (Model 92, IITC, Woodland Hills, CA, USA) coupled to a PowerLab 4/25 data acquisition system before and during the 8 weeks of treatment. After acclimatization with the BP measurement procedure, 3–8 readings of systolic BP of each conscious animal (with 5–10 min intervals) were recorded, and

mean values were calculated after values with large variations were discarded. Systolic BP was measured at 0, 4 and 8 weeks of treatment. All experimental variables such as temperature (27 °C), respiratory and body movements, as well as noise levels were minimized to ensure the best possible quality of data. The described noninvasive BP measurement is reported to have 96% correlation with direct BP (which leads to a variation of ± 10 mm Hg)⁸ and was recorded using a computer running Chart 5.3 software (ADInstruments, Sydney, Australia). Heart rate was calculated electronically using the cyclic measurements option of the Chart software. Ten days before the beginning of the experiment, rats were trained by exposing them daily to measurement condition for 1–2 h.

Blood pressure was also monitored invasively as described previously.⁹ Adult rats (180–200 g) of either sex were used. The animals were anesthetized with an intraperitoneal (i.p.) injection of sodium thiopental (Pentothal, 70–90 mg kg⁻¹ body weight), and arterial BP was recorded through carotid artery cannulation by a pressure transducer (MLT1199) coupled to a Bridge Amplifier and PowerLab 4/25 (ADInstruments). Drugs were injected through a cannula inserted into the jugular vein. After a 20-min period of equilibration equilibrium, the rats were injected intravenously with 0.1 ml saline (0.9% NaCl) or with the same volume of test substance. Arterial pressure was allowed to return to the resting level between injections. Control responses of standards, such as acetylcholine (ACh, 1 mg kg⁻¹) and norepinephrine (1 mg kg⁻¹), were obtained before the extracts were tested. Changes in mean arterial pressure (MAP) were recognized as the difference between the steady-state value before and the lowest reading after injection. MAP was calculated as the sum of the diastolic pressure (DP) and one-third of the pulse pressure (PP), where $PP=SP-DP$ (SP =systolic pressure).

Measurement of vascular reactivity in isolated rat aorta. At the end of the treatment, SHR and WKY rats were fasted for 16 h and anesthetized with diethyl ether by inhalation. Blood was collected through cardiac puncture and serum was analyzed for lipid profile and glucose level. Thoracic aortae were isolated and studied for endothelial reactivity.

The procedure described by Furchgott and Zawadzki¹⁰ was followed with some modifications. The descending thoracic aortae were transferred immediately into Krebs bicarbonate buffer (composition in mM: NaCl: 118.4, KCl: 4.7, CaCl₂: 2.5, KH₂PO₄: 1.2, MgSO₄: 1.2, NaHCO₃: 25 and glucose: 11), cleaned of periaortic tissue and cut transversally into ring segments (3 mm in length). Each ring was placed in a tissue bath filled with Krebs' buffer (37 °C), bubbled with carbogen (95% O₂ and 5% CO₂) and attached to a force transducer (model FORT100) coupled to a Transbridge (model TBM4M, World Precision Instruments, Hertfordshire, UK) and a PowerLab data acquisition system (model ML845, ADInstruments) and a computer running the Chart software (version 5.3) for measuring isometric tension. Rings were allowed to equilibrate for 60–90 min at a resting tension of 2 g with changes of buffer every 15 min. When the isometric tension had stabilized, inhibitory concentration–response curves (CRCs) of ACh (1×10^{-9} – 10^{-5} M) were constructed against contractions induced with a submaximal dose of PE (1×10^{-6} M).

Assessment of vasodilator and inhibition of calcium channels and calcium release activity in rabbit aortae. Direct vasodilator activity and its possible mode of action were studied using isolated rabbit aortae as described by Gilani *et al.*⁹ For the *in vitro* study, we preferred to use rabbits that are commonly used in our laboratory for different purposes, thus using multiple tissues from the same animals to maximize ethical and economical utilization. Rabbits were killed by cervical dislocation. The descending thoracic aortae were removed, cut into 2–3 mm wide rings and set up in a 5 ml tissue bath as described previously. After an equilibrium period of 1 h, the tissues were stabilized with a fixed dose of PE (1 μ M). The tissues were considered stable only when similar responses were obtained from repeated doses of PE, which usually took 60–90 min. Vasoconstricting effects of the extract were first determined on the resting baseline of the tissue. The extract was later tested for its ability to relax the contractions induced with PE (1 μ M) and high K⁺ (80 mM). To confirm the calcium channel blocking (CCB) activity, Ca²⁺ CRCs were constructed in a Ca²⁺-free medium. Subsequently, the effect of increasing dose of the extract was determined on the Ca²⁺ CRCs. A shift in the Ca²⁺ curves to the right would have confirmed CCB

activity. To determine whether the extract was also inhibiting the Ca^{2+} release from intracellular stores or blocking the calcium influx across the cell membrane (through the voltage-dependent or receptor-operated channels), the effect of increasing extract dose was observed on PE ($1\ \mu\text{M}$) peaks in Ca^{2+} -normal and in Ca^{2+} -free Krebs's solution, with Ca^{2+} omitted and EDTA (ethylenediaminetetraacetic acid) ($0.1\ \text{mM}$) added to ensure total elimination of extracellular Ca^{2+} without harmful effects on Ca^{2+} inside the cell.¹¹

Effect on tyloxapol-induced hyperlipidemia. The tyloxapol-induced hyperlipidemic model¹² was followed with slight modifications. Male SD rats weighing 160–180 g were randomly divided into three groups ($n=6$ each). Groups 1 and 2 were fed diet A (normal diet) and group 3 was fed diet B (normal diet with OM). After 10 days of the treatment, all animals were fasted for 7 h and group 1 received saline ($10\ \text{ml kg}^{-1}$; i.p.) whereas groups 2 and 3 were administered tyloxapol ($500\ \text{mg kg}^{-1}$; i.p.). On the following day, all animals were anesthetized by diethyl ether (by inhalation), and the blood was collected for analysis of serum total cholesterol (TC) and triglycerides (TGs).

Effect on high fat diet-induced hypercholesterolemia. The effect of OM on high fat diet-induced hypercholesterolemia was studied using the method described by Berroughui et al.¹³ with slight modifications introduced after pilot studies. Adult SD rats (12–14 weeks old, weighing 140–160 g) were randomly divided into three groups (7–10 in each). Group 1 was fed diet A (served as normal control), group 2 was fed diet C (atherogenic control) and group 3 was fed diet D (treated). Animals in all groups had free access to water and food. Diet consumption was monitored daily, and the gain in body weight was monitored weekly. At the end of 6 weeks of treatment, animals were fasted for 16 h before blood collection, and samples were analyzed for serum lipids and glucose levels.

Free radical scavenging activity. The method reported by Blois¹⁴ was followed with a slight modification. A $0.1\ \text{mM}$ solution of 1,1-diphenyl-2-picryl-hydrazil (DPPH) radical in methanol was prepared, and 1 ml of this solution was added to 3 ml of the extract solution in methanol at different concentrations. Absorbance was measured after 30 min at 517 nm using a Beckman DU-70 Spectrophotometer (Beckman Instruments, Fullerton, CA, USA). A decrease in the absorbance of DPPH solution indicates an increase in DPPH radical scavenging activity. The percentage of the radical scavenging activity of DPPH was calculated by the equation:

% DPPH radical scavenging =

$$\left(1 - \frac{\text{Control Absorbance} - \text{Sample Absorbance}}{\text{Control Absorbance}}\right) \times 100$$

The DPPH solution was used as the control. The CRCs were plotted as concentration of extracts in $\mu\text{g ml}^{-1}$ against the percentage of free radical

scavenging activity for the calculation of EC_{50} values along with the 95% confidence interval (95% CI).

Estimation of lipid profiles and glucose levels. Blood was collected in a vacutainer by cardiac puncture from anesthetized rats that were fasted overnight. The serum was separated after centrifugation at 3000 r.p.m./Eppendorf Centrifuge 5418 for 10 min. Serum lipids and glucose were assayed enzymatically using commercially available kits. Serum TC, high-density lipoprotein-cholesterol (HDL-C), TG and glucose levels were determined using methods described by the manufacturer (Randox Laboratories). Low-density lipoprotein-cholesterol (LDL-C) was estimated indirectly using the formula: $\text{LDL} = \text{TC} - \text{HDL} - \text{TG}/5$.¹⁵ The atherogenic index was calculated using the formula: $\text{atherogenic index} = \text{TC} - \text{HDL}/\text{HDL}$.

Safety assessment

Orchis mascula was evaluated for acute toxicity. Balb-C mice were divided into four groups of six and were administered increasing doses of the OM crude extract (1, 2 and $3\ \text{g kg}^{-1}$) in a $10\ \text{ml kg}^{-1}$ volume. A negative control group of mice was administered saline ($10\ \text{ml kg}^{-1}$, per oral (p.o.)). The mice were kept under observation for mortality and behavioral changes for 48 h and allowed food and water *ad libitum* during this time.

Statistical analysis

All data were expressed as means \pm s.e.m., and the median EC_{50} values were calculated as the geometric mean with 95% CIs. CRCs were analyzed by nonlinear regression. One-way analysis of variance (one-way ANOVA) followed by Tukey's post-test was used to determine significant differences in various biological parameters with and without treatment. Two-way ANOVA followed by Bonferroni's post-test correction was used for multiple comparisons of CRCs with control. P -values < 0.05 ($P < 0.05$) were considered statistically significant. All the graphing, calculations and statistical analyses were performed using GraphPad Prism software version 4.00 for Windows, (GraphPad Software, San Diego, CA, USA, <http://www.graphpad.com>).

RESULTS

Phytochemical screening

Qualitative phytochemical screening of the crude extract of ground powder of OM (Om.Cr) showed the presence of alkaloids, saponins, tannins, phenolics, terpenes, sterols and flavonoids.

Effects on BP and lipid profile in SHR

The treatment of SHR with OM for 8 weeks significantly reduced elevated systolic BP ($P < 0.05$), along with serum TGs, LDL-C and atherogenic index compared with untreated controls. No effects were observed on TC, HDL-C and glucose (Table 1). Treatment also

Table 1 Effects of *Orchis mascula* (OM) on blood pressure, serum lipids and glucose in SHR

Parameters	WKY	SHR	SHR+ <i>Orchis mascula</i>
Systolic BP (mm Hg)	140.7 \pm 3.4	203.4 \pm 7.13 ^{††}	174.2 \pm 9.63*
Heart rate (b.p.m.)	322.1 \pm 11.7	331.3 \pm 6.02	333.3 \pm 8.28
Total cholesterol (mg per 100 ml)	110.9 \pm 7.8	90.3 \pm 7.7	69.51 \pm 11.62
HDL-C (mg per 100 ml)	93.9 \pm 6.6	68.3 \pm 7.1 [†]	63.51 \pm 10.75
LDL-C (mg per 100 ml)	17 \pm 3.6	21.9 \pm 3.5	5.99 \pm 1.27*
Triglycerides (mg per 100 ml)	80.42 \pm 4.0	93.84 \pm 5.7 [†]	29.28 \pm 6.99**
Atherogenic index	0.183 \pm 0.04	0.36 \pm 0.08 ^{††}	0.096 \pm 0.017*
Glucose (mg per 100 ml)	116 \pm 8.9	89.6 \pm 12.0	97.78 \pm 23.74

Abbreviations: ANOVA, analysis of variance; BP, blood pressure; b.p.m., beats per minute; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SHR, spontaneously hypertensive rat; WKY, Wistar Koyoto.

One-way ANOVA followed by Tukey's post-test. WKY rats served as normotensive controls.

Values shown are mean \pm s.e.m. of 7–10 determinations

* $P < 0.05$; ** $P < 0.001$ compared with SHR control.

[†] $P < 0.05$; ^{††} $P < 0.01$ compared with normotensive WKY control.




Figure 1 Concentration–response curves showing the comparative vasorelaxant effects of acetylcholine (ACh) on phenylephrine (PE; 1 μM) induced vasoconstriction in aortae isolated from SHRs (hypertensive control), SHRs treated with 3% OM for two months (SHR+OM) and Wistar Kyoto rats (WKY, normotensive control). The symbols represent the means ± s.e.m. of 5–10 preparations. (** $P < 0.01$, *** $P < 0.001$; compared with untreated SHRs; two-way ANOVA followed by Bonferroni's post-test correction).

improved the endothelial-dependent relaxation of PE-induced contractions in isolated aortae compared with those of untreated controls. The comparative concentration curves of ACh in the aortae of different groups are presented in Figure 1.

Effects on BP in normotensive anesthetized rats

The crude extract of OM (Om.Cr) caused a dose-dependent (10 and 30 mg kg⁻¹) decrease in the BP of normotensive anesthetized rats. The doses of 10 and 30 mg kg⁻¹ induced a respective decrease of 14.5 ± 3.5 and 32 ± 3% (mean ± s.e.m.) in BP. Figure 2 (top) shows the tracing from a typical experiment, whereas the combined data obtained from different animals under the same experimental conditions have been plotted in Figure 2 (bottom).

Effect on isolated rabbit aortae

Isolated rabbit aortic ring preparations were used for the study of direct vasodilator activity and the possible mode of action(s) of OM. The crude extract of OM (Om.Cr) caused concentration-dependent (0.03–10.0 mg ml⁻¹) inhibition of both PE (EC₅₀, 95% CI; 2.6 mg per 100 ml, 1.86–3.76; $n=5$) and high K⁺-induced contractions (1.08 mg ml⁻¹, 0.92–1.28; $n=5$). The comparative curves are shown in Figure 3. On the endothelium of intact and denuded aortic rings of selected vascular preparation, no significant difference in the inhibitory effect of Om.Cr was found (data not shown). Om.Cr caused a concentration-dependent nonparallel rightward shift with the suppression of maximum response (31.87 ± 3.1 and 57.75 ± 6.9%, $P < 0.001$ vs. control) at 0.3 and 1.0 mg ml⁻¹, respectively, in calcium CRC (similar to those of verapamil) (24.5 ± 0.8 and 61.5 ± 3.2%, $P < 0.001$ vs. control) at 0.03 and 0.1 μM, respectively, as shown in Figure 4. Om.Cr also caused a concentration-dependent (0.3 and 1.0 mg ml⁻¹) rightward shift in the Ca²⁺ CRCs in a manner similar to that of verapamil, confirming the CCB activity (Figure 4). Furthermore, on the baseline, Om.Cr caused slight contractions at 0.3–3.0 mg ml⁻¹. The contractile effect of Om.Cr was partially blocked in phentolamine (1 μM) pretreated aortic rings, as shown in Figure 3. In Ca²⁺-free medium, PE (1 μM) caused a sharp contraction because of




Figure 2 Typical tracing showing the blood pressure-lowering effect of the crude extract of *Orchis mascula* (Om.Cr) (top) and bar chart representing the hypotensive effect of Om.Cr on mean arterial pressure (MAP) in anesthetized normotensive rats (bottom). The data represent the mean ± s.e.m. of 3 animals.




Figure 3 Effect of the crude extract of *Orchis mascula* (Om.Cr) on vascular contractions. The upper panel shows the effect of Om.Cr on basal tension without and with phentolamine (1 μM), in which the responses to each concentration were expressed as a percentage of the PE-induced contraction. The lower panel shows the vasodilator effect against phenylephrine (PE; 1 μM) and high K⁺ (80 mM) induced contractions in isolated rabbit aortic preparations. Values shown are means ± s.e.m. of 4–6 measurements.

the release of Ca^{2+} from intracellular stores. Om.Cr also caused a reduction in these contractions in a concentration-dependent manner (0.3–3 mg per 100 ml), similar to that of Verapamil (data not shown).




Figure 4 Effect of increasing the dose of *Orchis mascula* crude extract (Om.Cr) (top) and Verapamil (bottom) on Ca^{2+} concentration-response curves constructed in Ca^{2+} -free and K^{+} -rich (80 mM) medium in isolated rabbit aorta. Values shown are means \pm s.e.m. of 4–6 experiments. *** $P < 0.001$; compared with control maximum, two-way ANOVA followed by Bonferroni's post-test correction).

Effects on tyloxapol-induced hyperlipidemia

Administration of Tyloxapol (Triton WR-1339) caused an increase in serum TC, 526.6 ± 44.04 vs. 82.22 ± 3.131 mg per 100 ml ($P < 0.001$; $n=8-10$), and TGs, 6276 ± 541.6 vs. 67.83 ± 4.14 mg per 100 ml ($P < 0.001$; $n=8-10$), compared with normal controls. Pretreatment of the rats with OM protected partially against tyloxapol-induced hypercholesterolemia, 277.6 ± 84.7 mg per 100 ml ($P < 0.05$; $n=8$), and hypertriglyceridemia, 2823 ± 1139 mg per 100 ml ($P < 0.01$; $n=8$).

Effects on high fat diet-induced hyperlipidemia

An atherogenic diet significantly increased TC, LDL and the atherogenic index compared with controls. Supplementation of OM with an atherogenic diet prevented the increase in mean serum TC, LDL-C and the atherogenic index. The treatment did not exert any effect on HDL-C, TG and glucose levels. The decrease in body weight was accompanied by a slight reduction in daily diet consumption. The data are summarized in Table 2.

In vitro antioxidant activity

The crude extract of OM (Om.Cr) was devoid of antioxidant activity up to the maximum concentration ($150 \mu\text{g ml}^{-1}$) tested by the DPPH assay.

Safety assessment

In acute toxicity studies on mice, OM crude extract (Om.Cr) up to 3 g kg^{-1} , p.o. did not produce mortality in 48 h or any behavioral changes during the observation period. During chronic treatment for 6–8 weeks, OM did not cause any death or behavioral changes in normotensive and SHR rats.

DISCUSSION

In this study, chronic treatment of SHRs with OM significantly reduced systolic BP compared with untreated hypertensive controls. This may explain its medicinal use in hypertension. SHR is the most widely used animal model for human essential hypertension because of its similarities in genetic predisposition to high BP without specific etiology, increased total peripheral resistance without volume expansion, impairment of endothelial function and similar responses to drug treatment.¹⁶ The hypotensive effects of Om.Cr in normotensive anesthetized rats imply direct effects on the cardiovascular system, as BP is the product of cardiac output and peripheral vascular resistance¹⁷ and it effected a change in either or both of these parameters. The goal of any antihypertensive therapy is targeted to bring a reduction in either or both of these parameters, preferably peripheral vascular resistance.

Table 2 Effect of *Orchis mascula* (OM) on serum lipids, glucose, body weight and diet consumption in atherogenic diet

Parameters	Normal diet	Atherogenic diet	Atherogenic+Orchis mascula
Total cholesterol (mg per 100 ml)	82.2 ± 3.13	$356.1 \pm 18.04^{\dagger\dagger}$	$268.6 \pm 15.28^{**}$
HDL-C (mg per 100 ml)	38.5 ± 1.73	27.8 ± 3	32.51 ± 2.24
LDL-C (mg per 100 ml)	30.1 ± 2.34	$314.52 \pm 16.6^{\dagger\dagger}$	$183.4 \pm 38.99^{**}$
Triglycerides (mg per 100 ml)	59.7 ± 4.2	68.61 ± 8.44	80.18 ± 8.94
Atherogenic index	1.15 ± 0.09	$12.5 \pm 1.12^{\dagger\dagger}$	$7.49 \pm 0.91^{**}$
Glucose (mg per 100 ml)	95.6 ± 7.2	147 ± 19	92.85 ± 11.46
% change in body weight	33.33 ± 1.6	$56.8 \pm 1.97^{\dagger}$	$34.23 \pm 7.34^*$
Diet consumption g per day per kg	168.5 ± 11.8	146.1 ± 15.1	129.2 ± 8.6

Abbreviations: ANOVA, analysis of variance; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Values shown are mean \pm s.e.m. of 7–10 determinations.

$^{\dagger}P < 0.05$; $^{\dagger\dagger}P < 0.01$ compared with normal controls.

$^*P < 0.05$; $^{**}P < 0.01$ compared with atherogenic control. One-way ANOVA followed by Tukey's post-test.

Vascular resistance is regulated by the endothelium through the synthesis and secretion of various vasoactive substances. In SHR, vascular endothelial dysfunction is caused by various factors, such as hypertension,¹⁸ hypertriglyceridemia¹⁹ and the excess production of oxidants and/or deficiency of antioxidant systems.²⁰ Treatment of SHR with OM completely reversed endothelial dysfunction (indicated by increased vasorelaxation induced by ACh) comparable with WKY normotensive controls, and this effect was associated with a reduction in serum TGs, LDL-C and the atherogenic index. All of these are independent risk factors in the development of endothelial dysfunction.

Blood pressure is the product of cardiac output and peripheral vascular resistance. An increase in either or both of these results in hypertension. The ability of Om.Cr to relax the contractions induced by PE and high K⁺ in isolated rabbit aorta is indicative of the blockade of Ca²⁺ influx through both receptor-operated and L-type voltage-dependent Ca²⁺ channels, respectively.²¹ The Ca²⁺ channel blockade (CCB) activity of Om.Cr was further confirmed by the rightward shift of Ca²⁺ CRCs with the suppression of maximum response ($P < 0.001$ vs. control), caused by Om.Cr, similar to the effects of verapamil, a standard CCB used clinically.²² The beneficial effects of CCBs are due to multiple mechanisms, such as a direct relaxant effect on the cardiovascular system by blocking the entry of Ca²⁺ into the cells, an antidyslipidemic effect due to an increase in cholesteryl ester hydrolysis by increasing intracellular cyclic adenosine monophosphate and inherent antioxidant properties.²³ In Ca²⁺-free Krebs's solution, PE acts through stimulation of α_1 -adrenergic receptors followed by the conversion of phosphatidylinositol to inositol-1,4,5-trisphosphate, which in turn releases Ca²⁺ from the intracellular stores and brings about the contraction.²⁴⁻²⁵ In a normal Ca²⁺ Krebs's solution, the PE-stimulated contractions come about possibly through the influx of Ca²⁺ from the L-type voltage-dependent Ca²⁺ channels and the receptor-operated nonselective cation channels.²⁶ Om.Cr appears to inhibit both mechanisms. Furthermore, the presence of vasoconstrictor constituents may also explain the partial reversal of hypertension. However, further investigations are required to verify this.

To study the possible mode of action of the lipid-lowering activity of OM, tyloxapol and the high cholesterol diet-induced hyperlipidemia models were used. In tyloxapol-induced hyperlipidemia, OM caused a significant reduction in both serum TG and TC levels to levels comparable with controls. Tyloxapol caused an increase in serum TGs and cholesterol levels because of the increase in hepatic cholesterol synthesis, particularly by the increase in HMG Co-A activity²⁷ and by the inhibition of lipoprotein lipase (LPL) responsible for hydrolysis of plasma lipids.²⁸ This indicates the inhibition of lipid biosynthesis as a possible mechanism of the lipid-lowering effect of OM.

A high cholesterol diet induces endothelial dysfunction and atherosclerosis²⁹ and increases oxidative stress by increasing the expression of oxidation-sensitive genes, such as Elk-1 and p-CREB.³⁰ A high cholesterol diet with cholic acid increases TC, LDL-C and the atherogenic index and decreases HDL-C by enhancing intestinal absorption and secretion and decreasing the catabolism of cholesterol.³¹ A high-fat diet also causes oxidative stress (enzymatic and nonenzymatic) in rats, as indicated by increased levels of thiobarbituric acid reactive substances and conjugated dienes, significantly attenuated activities of superoxide dismutase, catalase, glutathione peroxidase and glutathione-S-transferase, as well as reduced glutathione levels in the liver, heart, kidney, intestine and aorta. Antioxidants effectively prevent this kind of cellular damage.³² The reduction of serum TC, LDL-C and the atherogenic index indicates

that OM reduces intestinal absorption and secretion and also possesses *in vivo* antioxidant activity. However, Om.Cr did not show *in vitro* antioxidant activity in the DPPH free radical scavenging assay. The presence of *in vivo* antioxidant activity of OM may prevent the disturbance in Ca²⁺ homeostasis, which is essential for the synthesis and release of nitric oxide from endothelial cells.³³ Furthermore, the reduction of body weight gain by OM may be due to the reduction in daily diet consumption, which may be useful in CVD associated with obesity. The phytochemical screening indicated the presence of phenolic acids, terpenes, flavonols and tannins, which are known antioxidants. Owing to the multifaceted nature of antioxidants, it may not be possible to rule out the presence of *in vitro* antioxidant activity in OM on the basis of a single assay.³⁴ Therefore, other methods such as reactive oxygen species scavenging assays and electron transfer-based assays should be attempted. Moreover, antioxidation is not the sole mechanism of the lipid-lowering activity of OM.

CONCLUSIONS

Antihypertensive and endothelial modulating effects of OM are mediated through multiple pathways that include a direct vasorelaxant effect through CCB and the inhibition of both lipid biosynthesis and intestinal absorption and secretion. This study rationalizes the medicinal use of OM in hypertension and dyslipidemia. However, further studies are required to isolate and identify active constituent(s) of OM responsible for its beneficial medicinal effects.

ACKNOWLEDGEMENTS

This study was supported by the Pakistan Science Foundation through research grant PSF/R&D/S-AKU/Bio (377).

- 1 Usmanhany K, Saeed A, Alam MT. *Indusynic Medicine: Traditional Medicine of Herbal, Animal and Mineral Origin in Pakistan*. B.C.C. and T. Press, University of Karachi: Karachi, 1997, pp 320-321.
- 2 Aziz N, Mehmood MH, Mandukhail SR, Bashir S, Raouf S, Gilani AH. Antihypertensive, antioxidant, antidyslipidemic and endothelial modulating activities of a polyherbal formulation (POL-10). *Vascul Pharmacol* 2009; **50**: 56-64.
- 3 Williamson EM, Okpako DT, Evans FJ. *Pharmacological Methods in Phytotherapy Research*. John Wiley & Sons: Chichester, 1998, pp 15-23.
- 4 National Research Council. *Guide for the Care and Use of Laboratory Animals*. National Academy Press: Washington, 1996, pp 1-7.
- 5 Tona L, Kambu K, Ngimbi N, Cimanga K, Vlietinck AJ. Antiamoebic and phytochemical screening of some Congolese medicinal plants. *J Ethnopharmacol* 1998; **6**: 57-65.
- 6 Harkness JE, Wagner JE. *The Biology and Medicine of Rabbits and Rodents*, 4th edn. Williams and Wilkins: Hagerstown, 1995.
- 7 Ichihashi T, Izawa M, Miyata K, Mizui T, Hirano K, Takagishi Y. Mechanism of hypocholesterolemic action of S-8921 in rats: S-8921 inhibits ileal bile acid absorption. *J Pharmacol Exp Ther* 1998; **284**: 43-50.
- 8 Rodrigo E, Maeso R, Munoz-Gracia R, Navarou-Cid J, Ruilope LM, Cachofeiro V, Lahera V. Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. *J Hypertens* 1997; **15**: 613-618.
- 9 Gilani AH, Jabeen Q, Ghayur MN, Janbaz KH, Akhtar MS. Studies on the antihypertensive, antispasmodic, bronchodilator and hepatoprotective activities of the *Carum copticum* seed extract. *J Ethnopharmacol* 2005; **98**: 127-135.
- 10 Furchtgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 1980; **299**: 373-376.
- 11 Guan YY, Kwan CY, Daniel EE. The effects of EGTA on vascular smooth muscle contractility in calcium free medium. *Can J Physiol Pharmacol* 1988; **66**: 1053-1056.
- 12 Khanna AK, Rizvi F, Chander R. Lipid lowering activity of *Phyllanthus niruri* in hyperlipemic rats. *J Ethnopharmacol* 2002; **82**: 19-22.
- 13 Berroughui H, Ettiab A, Herrera Gonzalez MD, Alvarez de Sotomayor M, Bennari-Kabchi N, Hmamouchi M. Hypolipidemic and hypocholesterolemic effect of argan oil (*Argania spinosa* L.) in Meriones Shawi rats. *J Ethnopharmacol* 2003; **89**: 15-18.
- 14 Blois MS. Antioxidant determinations by the use of a stable free radical. *Nature* 1958; **26**: 1199-1200.
- 15 Friedwald WT, Levy R L, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. *Clin Chem* 1972; **18**: 499.

- 16 Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. *Circ Res* 1977; **41**: 19–26.
- 17 Johansen PL. Hemodynamic effects of calcium antagonists in hypertension. In Epstein M. (ed). *Calcium Antagonists in Clinical Medicine*. Hanley and Belfus Inc: Philadelphia, 1992, pp 69–88.
- 18 Vanhoutte PM, Boulanger CM. Endothelium-dependent responses in hypertension. *Hypertens Res* 1995; **18**: 87–98.
- 19 Bartus M, Lomnicka M, Lorkowska B, Franczyk M, Kostogrys RB, Pisulewski PM, Chlopicki S. Hypertriglyceridemia but not hypercholesterolemia induces endothelial dysfunction in the rat. *Pharmacol Rep* 2005; **57**(Suppl): 127–137.
- 20 Akpaffiong MJ, Taylor AA. Antihypertensive and vasodilator actions of antioxidants in spontaneously hypertensive rats. *Am J Hypertens* 1998; **11**: 1450–1460.
- 21 Karaki H, Ozaki H, Hori M, Mitsui-Saito M, Amano K, Harada K, Miyamoto S, Nakazawa H, Won KJ, Sato K. Calcium movements, distribution, and functions in smooth muscle. *Pharmacol Rev* 1997; **49**: 157–230.
- 22 Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. *Pharmacol Rev* 1986; **38**: 312–416.
- 23 Etingin OR, Hajjar DP. Calcium channel blockers enhance cholesteryl ester hydrolysis and decrease total cholesterol accumulation in human aortic tissue. *Circ Res* 1990; **66**: 185–190.
- 24 Cauvin C, Malik S. Induction of calcium influx and calcium release in isolated rat aorta and mesenteric resistance vessels by norepinephrine activation of α -receptors. *J Pharmacol Exp Ther* 1984; **230**: 413–418.
- 25 Hashimoto M, Hirata M, Itoh T, Kanmura Y, Kuriyama H. Inositol 1, 4, 5-triphosphate activates pharmacomechanical coupling in smooth muscle of rabbit mesenteric artery. *J Physiol* 1986; **370**: 605–618.
- 26 Karaki H. Inhibitory effects of calcium channel blockers in vascular smooth muscle. In *Proceedings of the Asia-Pacific Symposium on Ca-Antagonists, Tokyo*. Churchill Livingstone: New York, 1993, pp 3–11.
- 27 Kuroda M, Tanzawa K, Tsujita Y, Endo A. Mechanism for elevation of hepatic cholesterol synthesis and serum cholesterol levels in Triton WR-1339-induced hyperlipidemia. *Biochim Biophys Acta* 1977; **489**: 119–125.
- 28 Schotz MC, Scanu A, Page IH. Effect of Triton on lipoprotein lipase of rat plasma. *Am J Physiol* 1957; **188**: 399–402.
- 29 Hayashi T, Ishikawa T, Naito M, Kuzuya M, Funaki C, Asai K, Kuzuya F. Low level hyperlipidemia impairs endothelium-dependent relaxation of porcine coronary arteries by two mechanisms. Functional change in endothelium and impairment of endothelium-dependent relaxation by two mediators. *Atherosclerosis* 1991; **87**: 23–38.
- 30 de Nigris F, Lerman A, Ignarro LJ, Williams-Ignarro S, Sica V, Baker AH, Lerman LO, Geng YJ, Napoli C. Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis. *Trends Mol Med* 2003; **9**: 351–359.
- 31 Heuman DM, Vlahcevic ZR, Bailey ML, Hylemon PB. Regulation of bile acid synthesis II. Effect of bile acid feeding on enzymes regulating hepatic cholesterol and bile acid synthesis in the rat. *Hepatology* 1988; **8**: 892–897.
- 32 Vijayakumar RS, Surya D, Nalini N. Antioxidant efficacy of black pepper (*Piper nigrum* L.) and piperine in rats with high fat diet induced oxidative stress. *Redox Report* 2004; **9**: 105–110.
- 33 Pogan L, Garneau L, Bissonnette P, Wu L, Sauve R. Abnormal Ca^{2+} signalling in vascular endothelial cells from spontaneously hypertensive rats: role of free radicals. *J Hypertens* 2001; **19**: 721–730.
- 34 Huang D, Ou B, Prior RL. The chemistry behind antioxidant capacity assays. *J Agric Food Chem* 2005; **53**: 1841–1856.